Search for: "TAKEDA PHARMA V TEVA PHARMA" Results 61 - 68 of 68
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
30 Apr 2019, 7:22 am
  This is a different concern to Shingrix where the claim did “necessarily and specifically” (i.e. the test set down by the CJEU in Teva v Gilead) cover the product but included non-medicinal ingredients. [read post]
19 Dec 2019, 9:41 am
  In his reference, the Judge trotted through the English court's and CJEU's case law Article 3(a) - Takeda, Farmitalia, Daiichi, Yeda, Medeva (and its progeny), Actavis v Sanofi, Eli Lilly v HGS, Actavis v Boehringer, - and found that it was clear that something more was required, but what that "something" was was not clear. [read post]
13 Jun 2008, 3:40 am
: (Patent Docs), Generic drug developers will continue to take advantage of global demand for lower-priced drugs, with Teva poised to maintain lead position says Goldman Sachs analyst: (GenericsWeb), Daiichi Sankyo takeover of Ranbaxy: (Profitability through Simplicity), (Spicy IP), (GenericsWeb), Canada: Generics to penetrate 26% pharma market in Canada says RNCOS research: (GenericsWeb), Canada: Generic drug makers spreading misinformation about patent regulation amendments to… [read post]
28 Apr 2008, 11:00 am
: Art, access and the public domain after Bridgeman v Corel’ – 29 April, New York City: (creativecommons.org), (Public Knowledge) US: ACI ‘Paragraph IV disputes’ conference – 30 April – 1 May, New York City: (Orange Book Blog) Pharma & Biotech Pharma & Biotech - General Canada: Patented Medicine Prices Review Board (PMPRB) departs from its guidelines in determining price in recent… [read post]
11 Apr 2008, 9:00 am
’ – 18 – 22 June, US/Alaska: (Public Knowledge), Center for IP 8th Annual IP Symposium – 28-30 May, Maryland US: (Public Knowledge), University of Maastricht: Conference on public health, innovation and intellectual property – 15 April, Maastricht (Netherlands): (IPR-Helpdesk), NLSIU Symposium: ‘Challenges to India’s patent regime’ – 12-13 April: (Spicy IP), Anti-counterfeiting and brand… [read post]